ReviewProceedings of the Japan Academy. Series B, Physical and biological sciences2011
Ivermectin, 'wonder drug' from Japan: the human use perspective.
Review in Proceedings of the Japan Academy. Series B, Physical and biological sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.The Journal of antibiotics · 2020Pooled it
- Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection.The Cochrane database of systematic reviews · 2016Pooled it
- Chemoprophylaxis against COVID-19 among health-care workers using Ivermectin in low- and middle-income countries: A systematic review and meta-analysis.Indian journal of pharmacologyPooled it
- Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial.PLoS neglected tropical diseases · 2023Trial
- Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial.Respirology (Carlton, Vic.) · 2022Trial
- Effects of Three Anthelmintics on the Transcriptome of FHs 74 Int Enterocytes.Tropical medicine and infectious disease · 2026Article
- Changing Species Dynamics and Species-Specific Associations Observed between Anopheles and Plasmodium Genera in Diebougou Health District, Southwest Burkina Faso.The American journal of tropical medicine and hygiene · 2026Article
- Interactions at theMicrobiology (Reading, England) · 2026Review
- Bioprospecting Indoor Bacteria Producing Bioactive Metabolites.Environmental microbiology reports · 2026Article
- Review
- Massive scabies outbreak in Rohingya refugee camps, Cox's Bazar: Epidemiology and impact of a mass drug administration (MDA) campaign - A retrospective study.PLoS neglected tropical diseases · 2026Observational
- Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs.PLoS pathogens · 2026Article
- Article
- Integrated in vitro and in vivo evaluation of ivermectin hydrogel formulation for management of scabies with pharmacological assessment.Scientific reports · 2026Article
- Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs.bioRxiv : the preprint server for biology · 2026Article
- Ivermectin exposition during neurulation induces neural tube defects and neuromuscular alterations inFrontiers in pharmacology · 2026Article
- Global research hotspots, trends, and future directions of ivermectin research: an informatics investigation (2020-2025).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Host-targeted oral avian vaccine virus demonstrates broad antiviral activity and safety in patients.Frontiers in immunology · 2026Review
- Onchocerciasis overview: pathogenesis, clinical spectrum, and therapeutic challenges of a neglected tropical disease.Frontiers in parasitology · 2026Review
- Article
80 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Discovered in the late-1970s, the pioneering drug ivermectin, a dihydro derivative of avermectin--originating solely from a single microorganism isolated at the Kitasato Institute, Tokyo, Japan from Japanese soil--has had an immeasurably beneficial impact in improving the lives and welfare of billions of people throughout the world. Originally introduced as a veterinary drug, it kills a wide range of internal and external parasites in commercial livestock and companion animals. It was quickly discovered to be ideal in combating two of the world's most devastating and disfiguring diseases which have plagued the world's poor throughout the tropics for centuries. It is now being used free-of-charge as the sole tool in campaigns to eliminate both diseases globally. It has also been used to successfully overcome several other human diseases and new uses for it are continually being found. This paper looks in depth at the events surrounding ivermectin's passage from being a huge success in Animal Health into its widespread use in humans, a development which has led many to describe it as a "wonder" drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.